3-[1-Oxo-6-(1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-9-yloxy)-3,4-dihydroisoquinolin-2-yl]propanoic acid | 866184-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 3-[1-Oxo-6-(1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-9-yloxy)-3,4-dihydroisoquinolin-2-yl]propanoic acid
• 英文别名: 3-[1-oxo-6-(1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-9-yloxy)-3,4-dihydroisoquinolin-2-yl]propanoic acid
• CAS: 866184-66-9
• 化学式: C₂₂H₂₂N₄O₄
• 分子量: 406.441
• InChiKey: ICQZVEJBMQHJOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  30
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  96.7
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Ethyl 3-[6-(3-fluoro-2-nitrophenoxy)-1-oxo-3,4-dihydroisoquinolin-2-yl]propanoate 在 氯化亚砜 、 10% palladium on activated carbon 、 水 、 氢气 、 四丁基碘化铵 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二甲基亚砜 为溶剂， 120.0 ℃ 、101.33 kPa 条件下， 生成 3-[1-Oxo-6-(1,2,3,4-tetrahydropyrimido[1,2-a]benzimidazol-9-yloxy)-3,4-dihydroisoquinolin-2-yl]propanoic acid
  参考文献：
  名称：

  Synthesis and initial evaluation of novel, non-peptidic antagonists of the αv-integrins αvβ3 and αvβ5

  摘要：

  The discovery, synthesis and preliminary SAR of a novel class of non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5) is described. High-throughput screening of an extensive series of ECLiPS (TM) compound libraries led to the identification of compound 1 as a dual inhibitor of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5). Optimization of compound 1 involving, in part, introduction of two novel constraints led to the discovery of compounds 15a and 15b with reduced PSA and much improved potency for both the alpha(v)beta(3) and alpha(v)beta(5) integrins. Compounds 15a and 15b were shown to have promising activity in functional cellular assays and compound 15a also exhibited a promising Caco-2 permeability profile. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.074

文献信息

• Nitrogen heterocycle biaryls for osteoporosis and other diseases
  申请人：Letourneau John Jeffrey

  公开号：US20050222203A1

  公开（公告）日：2005-10-06

  Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed. A representative example is

  氮杂环联苯具有羧酸末端，可用于治疗子宫内膜异位症、骨质疏松症、血管成形术后再狭窄、类风湿关节炎、癌症、黄斑变性和肥胖症。 公开了以下化合物的结构： 代表性示例是
• NITROGEN HETEROCYCLE BIARYLS FOR OSTEOPOROSIS AND OTHER DISEASES
  申请人：Letourneau John Jeffrey

  公开号：US20080051423A1

  公开（公告）日：2008-02-28

  Nitrogen heterocycle biaryls having a carboxylate terminus are useful for treating endometriosis, osteoporosis, restenosis following angioplasty, rheumatoid arthritis, cancer, macular degeneration and obesity. Compounds of formula: are disclosed. A representative example is
• US7365209B2
  申请人：——

  公开号：US7365209B2

  公开（公告）日：2008-04-29
• Synthesis and initial evaluation of novel, non-peptidic antagonists of the αv-integrins αvβ3 and αvβ5
  作者：Jeffrey J. Letourneau、Jinqi Liu、Michael H.J. Ohlmeyer、Chris Riviello、Yajing Rong、Hong Li、Kenneth C. Appell、Shalini Bansal、Biji Jacob、Angela Wong、Maria L. Webb

  DOI：10.1016/j.bmcl.2008.11.074

  日期：2009.1

  The discovery, synthesis and preliminary SAR of a novel class of non-peptidic antagonists of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5) is described. High-throughput screening of an extensive series of ECLiPS (TM) compound libraries led to the identification of compound 1 as a dual inhibitor of the alpha(v)-integrins alpha(v)beta(3) and alpha(v)beta(5). Optimization of compound 1 involving, in part, introduction of two novel constraints led to the discovery of compounds 15a and 15b with reduced PSA and much improved potency for both the alpha(v)beta(3) and alpha(v)beta(5) integrins. Compounds 15a and 15b were shown to have promising activity in functional cellular assays and compound 15a also exhibited a promising Caco-2 permeability profile. (C) 2009 Elsevier Ltd. All rights reserved.